Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 7 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Mountain Crest Acquisition Corp II | 1,031,805 | reported | 18 Dec 2023 | tx 10+1,143,438 |
| Tricida, Inc. | 256,000 | reported | 28 Feb 2022 | tx 26+1,313,681−55,731 |
| Anacor Pharmaceuticals Inc | 173,000 | reported | 23 Mar 2015 | tx 41+594,470−80,000 |
| Allogene Therapeutics, Inc. | 152,480 | reported | 02 Feb 2026 | tx 15+3,698,666−101,510 |
| PERRIGO Co plc | 36,217 | reported | 14 May 2026 | tx 60+201,394−88,080 |
| SUNESIS PHARMACEUTICALS INC | 25,000 | reported | 31 May 2017 | tx 9+169,485 |
| GENOPTIX INC | 4,167 | reported | 25 Feb 2011 | tx 5+15,000−833 |
| ChemoCentryx, Inc. | 0 | reported | 20 Oct 2022 | tx 67+450,450−481,146 |
| GENOMIC HEALTH INC | 0 | reported | 08 Nov 2019 | tx 10+47,538−47,538 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 14 May 2026 | EXERCISE | PERRIGO Co plc | 7,305 | 10.84 USD | |
| 14 May 2026 | TAX_WITHHOLDING | PERRIGO Co plc | 3,507 | 10.84 USD | |
| 13 May 2026 | GRANT_AWARD | PERRIGO Co plc | 16,681 | — | deriv |
| 14 May 2026 | EXERCISE | PERRIGO Co plc | 7,305 | — | deriv |
| 13 Mar 2026 | GRANT_AWARD | PERRIGO Co plc | 3,024 | — | deriv |
| 02 Feb 2026 | GRANT_AWARD | Allogene Therapeutics, Inc. | 539,072 | 0.00 USD | deriv |
| 02 Feb 2026 | GRANT_AWARD | Allogene Therapeutics, Inc. | 152,480 | 0.00 USD | deriv |
| 02 Feb 2026 | SALE | Allogene Therapeutics, Inc. | 24,001 | 1.76 USD | |
| 12 Dec 2025 | GRANT_AWARD | PERRIGO Co plc | 2,140 | — | deriv |
| 12 Nov 2025 | PURCHASE | PERRIGO Co plc | 7,500 | 14.18 USD | |
| 21 Oct 2025 | SALE | Allogene Therapeutics, Inc. | 36,744 | 1.26 USD | |
| 12 Sept 2025 | GRANT_AWARD | PERRIGO Co plc | 1,263 | — | deriv |
| 18 Aug 2025 | PURCHASE | PERRIGO Co plc | 4,375 | 22.97 USD | |
| 13 Jun 2025 | GRANT_AWARD | PERRIGO Co plc | 976 | — | deriv |
| 14 May 2025 | TAX_WITHHOLDING | PERRIGO Co plc | 4,754 | 26.01 USD | |
| 14 May 2025 | EXERCISE | PERRIGO Co plc | 9,904 | 26.01 USD | |
| 14 May 2025 | EXERCISE | PERRIGO Co plc | 9,904 | — | deriv |
| 14 May 2025 | GRANT_AWARD | PERRIGO Co plc | 7,305 | — | deriv |
| 12 May 2025 | PURCHASE | PERRIGO Co plc | 3,500 | 27.10 USD | first after silence |
| 03 Feb 2025 | SALE | Allogene Therapeutics, Inc. | 4,361 | 1.73 USD | |
| 24 Jan 2025 | GRANT_AWARD | Allogene Therapeutics, Inc. | 173,913 | 0.00 USD | |
| 24 Jan 2025 | GRANT_AWARD | Allogene Therapeutics, Inc. | 614,844 | 0.00 USD | deriv |
| 21 Oct 2024 | TAX_WITHHOLDING | Allogene Therapeutics, Inc. | 36,404 | 2.84 USD | |
| 16 May 2024 | GRANT_AWARD | Allogene Therapeutics, Inc. | 344,828 | 2.90 USD | |
| 15 May 2024 | EXERCISE | PERRIGO Co plc | 8,764 | 30.22 USD |
2 purchases reported after at least 12 months of silence — most recent on 12 May 2025.